Prolight Diagnostics

BioStock - Connecting Innovation and Capital publishes the article "Prolight Diagnostics advances towards validation of test for myocardial infarction diagnostics" Prolight Diagnostics’ report for the second quarter marks significant progress in developing the point-of-care analysis system Psyros. Not least, the company received a British grant of SEK 17 million, allowing them to initiate a pre-validation study on whole blood samples from patients with suspected myocardial infarction. The first results from the study are expected in the fourth quarter of 2024. Read the full article here: https://lnkd.in/dM8SNhXz

Emergers publicerar uppdaterad analys om Prolight Diagnostics där de står fast vid ett motiverat värde om 1,1-1,2 kronor per aktie. Läs artikeln här: https://lnkd.in/dWB7zXGM

Prolight Diagnostics receives positive feedback at ADLM Congress – We are very encouraged by the congress as we noticed even greater interest from the large diagnostic companies than in previous years and consistently received very positive feedback from potential customers and partners, said CEO Ulf Bladin. Read the full article at: https://lnkd.in/dZ8qNcGv

Prolight showcases the latest Psyros™ instrument and cartridge designs at the 2024 ADLM Clinical Lab Expo in Chicago, USA! The Psyros™ POC system continues to develop at incredible pace, for the latest updates please visit us at our ADLM DxPx booth or website www.prolightdx.com

Prolight Diagnostics presents the Psyros system at ADLM, one of the world’s largest and most important diagnostics congresses Prolight Diagnostics (“Prolight”), developer of the Psyros™ digital point-of-care (POC) system for high-sensitivity troponin, announces that the platform will be showcased at DxPx during the international congress ADLM in Chicago July 28-August 1, 2024. “We are very proud to present the latest commercial instrument prototype and the cartridge that will be used for high-sensitivity troponin assays. Given our unique POC digital immunoassay technology, which counts single molecules, we anticipate there will be great interest. Our technology provides a unique opportunity to test with high sensitivity and accuracy on a POC instrument in near-patient settings. We look forward to constructive conversations with potential commercial partners during the congress”, says Ulf Bladin, CEO of Prolight. Read the full press release here: https://lnkd.in/dzUFfkRN

– We believe the MicroFlex platform has potentially broad appeal to a range of different companies wishing to enter or improve their offering in the distributed immuno-diagnostic space, says Ben Metcalf, consultant at TTP plc. #BioStockSwe #LifeScience

Prolight Diagnostics vd Ulf Bladin besökte BioStocks studio för att berätta om bolagets patientnära analyssystem och framstegen i utvecklingen under 2024. #BioStockSwe #LifeScience

BioStock - Connecting Innovation and Capital publishes article "Prolight Diagnostics strengthens board with experienced business developer" Prolight Diagnostics expands its Board of Directors with Kiarash Farr, who has extensive experience in sales, business development and diagnostics. – I hope and believe that my experience will contribute to Prolight Diagnostics’ business development and market launch, says Kiarash Farr Read the full article at: https://lnkd.in/d3peFpaP

BioStock - Connecting Innovation and Capital publishes article "Prolight Diagnostics CSO comments on latest data" Supported by the latest data from its Psyros point-of-care system, Prolight Diagnostics is ready to initiate pre-validation trials using fresh whole blood and banked plasma patient samples to measure troponin. – The lower the detection limit of the system, the more accurately it can measure troponin at the relevant concentrations. This is where Psyros single-molecule counting system has a strong competitive advantage, says Prolight Diagnostics’ CSO Aileen McGettrick. Read the full article at: https://lnkd.in/decpv-sN

BioStock - Connecting Innovation and Capital publishes article "Prolight Diagnostics’ CTO thrilled to receive UK government grant" Prolight Diagnostics has been awarded a SEK 17 million grant from National Institute for Health and Care Research’s i4i Product Development Awards, supporting the development of the Psyros point-of-care test for heart attack. The grant will fund a pre-validation study at St Thomas’ Hospital to assess the performance of the Psyros system prior to the clinical validation in 2025. – Securing this highly competitive and prestigious grant represents a significant achievement for the company, says Prolight’s CTO Steve Ross. Read the full article at: https://lnkd.in/dvTaAnWx